Is MSA Similar to ALS? Similarities and Key Differences

Multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS) are both progressive, fatal neurodegenerative diseases with no cure, but they attack different structures in the nervous system and produce distinct clinical pictures. The confusion between them is understandable: both can cause stiffness, difficulty speaking, and eventual respiratory failure. Yet the underlying biology, the day-to-day experience of symptoms, and the trajectory of each illness differ in ways that matter for diagnosis and care.

What Each Disease Targets

The most fundamental difference between MSA and ALS is which parts of the nervous system they destroy. ALS attacks motor neurons, the nerve cells that run from the brain through the spinal cord to the muscles. When those cells die, muscles weaken, waste away, and eventually stop working. The disease hits both “upper” motor neurons (in the brain) and “lower” motor neurons (in the spinal cord and brainstem), which is why ALS produces a distinctive mix of weakness, muscle wasting, and stiffness.

MSA, by contrast, does not primarily target motor neurons. Instead, it damages three systems that work together behind the scenes: the autonomic nervous system (which controls blood pressure, bladder function, digestion, and other involuntary processes), the cerebellum (which coordinates balance and smooth movement), and the basal ganglia (which help initiate and regulate movement). People with MSA develop symptoms that look more like Parkinson’s disease or cerebellar ataxia, combined with severe autonomic failure. The disease is driven by abnormal clumps of a protein called alpha-synuclein that accumulate in brain support cells, placing MSA in a family of disorders known as synucleinopathies alongside Parkinson’s disease and Lewy body dementia.

ALS belongs to a different biological family. While its precise causes vary from person to person, the hallmark pathology involves accumulation of a protein called TDP-43 inside dying motor neurons. These are fundamentally different proteins misbehaving in fundamentally different cell types, which is why the two diseases, despite some surface-level overlap, require different diagnostic approaches.

Where Symptoms Overlap

Despite targeting different parts of the nervous system, MSA and ALS share a handful of symptoms that can blur the boundary between them, especially early on. Both diseases can cause muscle stiffness, difficulties with speech and swallowing, and eventual breathing problems. Both progress relentlessly, and both typically run their course within several years of symptom onset. It is easy to see why a patient or even a physician might initially wonder whether the two conditions could be one and the same.

Speech problems illustrate the overlap well. In ALS, speech becomes slurred and eventually unintelligible as bulbar motor neurons fail. In MSA, speech can also deteriorate, though often it becomes soft, monotone, or irregularly paced rather than frankly slurred, depending on whether the cerebellar or parkinsonian form predominates. Both conditions can lead to difficulty swallowing, increasing the risk of aspiration pneumonia. And both diseases can cause respiratory failure, which is the most common cause of death in ALS and a frequent late complication of MSA.

How the Motor Symptoms Differ

Although stiffness and movement problems appear in both diseases, the character of those symptoms is quite different on close examination. In ALS, muscle rigidity is “spastic” in nature, caused by damage to upper motor neurons. That rigidity gets worse with faster movement, tends to be more pronounced in the legs than the arms, and is often accompanied by a stiff, awkward gait.¹ Alongside that stiffness, ALS causes visible muscle wasting and twitching (fasciculations) as lower motor neurons die. The combination of weakness, wasting, and spasticity in the same person is one of the most recognizable signatures of ALS.

MSA’s motor symptoms follow a different pattern. In the parkinsonian form (MSA-P), people develop slowness of movement, rigidity, and sometimes tremor that resembles Parkinson’s disease. The key difference from Parkinson’s is that MSA-P responds poorly or not at all to levodopa, the standard Parkinson’s medication. In the cerebellar form (MSA-C), the dominant problem is coordination rather than stiffness: a wide-based, unsteady gait, clumsy hand movements, and scanning speech (where syllables come out unevenly). Neither form of MSA typically involves the dramatic muscle wasting and fasciculations that define ALS.

The Autonomic Divide

If you had to pick the single feature that most cleanly separates MSA from ALS in everyday life, it would be autonomic failure. MSA attacks the autonomic nervous system early and severely. Orthostatic hypotension, a dangerous drop in blood pressure when standing up, is one of the hallmark symptoms: people with MSA may faint or feel lightheaded simply by getting out of a chair. Bladder dysfunction, including urinary urgency, incomplete emptying, and incontinence, often appears before the motor symptoms are even recognized. Erectile dysfunction in men, constipation, and impaired temperature regulation round out a picture of widespread autonomic collapse.

ALS, by comparison, largely spares the autonomic nervous system for most of its course. Patients may develop some mild autonomic changes late in the disease, but severe early orthostatic hypotension, prominent urinary incontinence, and the kind of global autonomic failure seen in MSA are not typical. When a patient presenting with stiffness and speech difficulty also has severe blood pressure drops on standing and early bladder incontinence, clinicians should think of MSA. When those autonomic red flags are absent and progressive weakness with wasting dominates, ALS is far more likely.

Cognitive and Behavioral Changes

For decades, ALS was considered a disease of pure motor neuron loss, with thinking and personality left intact. That picture has changed dramatically. Research now shows that some degree of cognitive impairment affects up to about two-thirds of people with ALS, and roughly one in seven develops frank dementia, often a form of frontotemporal dementia that affects personality, decision-making, and language.² When ALS overlaps with frontotemporal dementia, survival tends to be shorter than with either disease alone.²

MSA, on the other hand, traditionally spares cognition to a greater extent. While some studies have identified mild executive function problems in MSA patients, the profound personality changes and language breakdown seen in ALS-frontotemporal dementia overlap are unusual. This difference matters both for distinguishing the two diseases and for understanding what daily life looks like for patients and caregivers. A person with ALS may gradually lose the ability to make decisions or manage finances even while their motor symptoms are still relatively early, whereas a person with MSA is more likely to remain cognitively sharp while dealing with escalating physical and autonomic challenges.

How Brain Imaging Helps Tell Them Apart

When symptoms are ambiguous, brain scans can offer important clues. On MRI, ALS may show early shrinkage of the frontal and temporal lobes of the brain, reflecting the spread of disease beyond the motor system. A PET scan measuring brain metabolism in ALS tends to reveal reduced activity in the frontal and parietal regions, while the basal ganglia look normal.¹

MSA produces a different imaging signature. The basal ganglia themselves show metabolic decline on PET, and MRI may reveal characteristic changes in the brainstem and cerebellum, including a finding sometimes called the “hot cross bun” sign in the pons (a cross-shaped pattern on MRI that is fairly specific to MSA-C). Shrinkage of the cerebellum and middle cerebellar peduncles is another hallmark. These imaging distinctions are not always obvious in the earliest stages of either disease, but as the illness progresses, the patterns diverge enough to be diagnostically useful.¹

When One Disease Masquerades as the Other

The existence of published case reports in which ALS was initially misdiagnosed as MSA tells you something about how tricky the early stages can be. One well-documented case described a patient who first presented with parkinsonian features and prominent anxiety, leading clinicians to suspect MSA-P. Only as the disease progressed did typical ALS signs emerge, including the muscle wasting and upper-motor-neuron features that pointed to the true diagnosis.¹

Misdiagnosis in either direction can happen because the two diseases share some surface features and because neither disease has a simple blood test or single scan that confirms it with certainty. ALS diagnosis relies heavily on electromyography (EMG) to detect the pattern of motor neuron loss in multiple body regions, and MSA diagnosis depends on a constellation of clinical criteria rather than a single definitive biomarker. Both diagnoses can be confirmed definitively only by autopsy pathology. This diagnostic uncertainty is one reason neurologists follow patients over time, watching how symptoms evolve before committing to a diagnosis.

Certain clues can prompt a clinician to reconsider an initial impression. In the case above, the presence of velocity-dependent spasticity (where resistance to movement increases when the limb is moved faster) pointed toward upper motor neuron involvement characteristic of ALS rather than the lead-pipe rigidity of parkinsonism seen in MSA.¹ Progressive muscle wasting and fasciculations, which are not part of the MSA picture, are among the strongest signals that the diagnosis needs revisiting.

Shared Biological Threads

Although MSA and ALS attack different cell types and involve different misfolded proteins, they share some underlying biology at the cellular level. Neuroinflammation, a state in which the brain’s immune system becomes chronically activated, is a consistent finding in ALS despite the wide variety of genetic and environmental factors that can trigger the disease. This inflammation involves activation of local support cells in the brain and spinal cord as well as infiltration by immune cells from the bloodstream.³ MSA also features significant neuroinflammation, with activated glial cells surrounding the alpha-synuclein deposits that define the disease.

Oxidative stress is another common denominator. In ALS, excessive production of reactive oxygen species paired with weakened antioxidant defenses contributes to the degeneration and death of motor neurons.⁴ Similar oxidative damage has been documented in MSA. Both diseases also involve mitochondrial dysfunction, where the energy-producing structures inside cells stop working efficiently. These shared downstream mechanisms suggest that even when the initial trigger differs, the final common pathway to cell death may have significant overlap. Researchers are interested in whether therapies targeting neuroinflammation or oxidative stress could potentially benefit both conditions, though no treatment has yet proven effective at halting either disease.

Prognosis and the Shape of Decline

Both MSA and ALS carry a poor prognosis, but the timeline and the nature of the decline differ in ways that affect daily life and planning. ALS typically progresses over two to five years from diagnosis, though a meaningful minority of patients live longer. The trajectory depends partly on where the disease starts: people whose symptoms begin with limb weakness tend to survive somewhat longer than those who first develop speech and swallowing problems (bulbar onset). Respiratory failure from progressive weakening of the breathing muscles is the usual cause of death, and the decision about whether to pursue mechanical ventilation is one of the most consequential choices ALS patients and families face.

MSA tends to progress over a slightly longer window, with average survival from symptom onset often cited in the range of six to ten years, though this varies considerably. The decline in MSA is driven by a different set of complications. Autonomic failure can cause dangerous blood pressure instability and recurrent falls. Swallowing difficulties and recurrent aspiration pneumonia become serious problems. Vocal cord paralysis, which can occur in MSA, occasionally leads to sudden respiratory emergencies, including stridor (a high-pitched sound during breathing) that may require urgent treatment. In late stages, patients may become wheelchair-bound and require full-time assistance, but their cognitive clarity often persists longer than in ALS cases involving frontotemporal involvement.

Treatment Differences

Neither MSA nor ALS can be cured, but the treatment strategies differ because the symptom profiles differ. For ALS, a small number of medications have been approved that modestly slow disease progression, including riluzole, which has been available since the mid-1990s, and edaravone, a more recent addition. A newer drug, tofersen, targets a specific genetic form of ALS caused by mutations in the SOD1 gene and represents a step toward genetically tailored therapy. Beyond disease-modifying drugs, ALS management centers on maintaining function for as long as possible through respiratory support (noninvasive ventilation), feeding tubes when swallowing becomes unsafe, and communication devices as speech fails.

MSA management is largely symptomatic. Medications to raise blood pressure (like midodrine or droxidopa) help manage orthostatic hypotension. Constipation, bladder dysfunction, and sleep-related breathing problems each require their own interventions. Unlike Parkinson’s disease, MSA responds poorly to levodopa, which is itself a diagnostic clue: if a patient with parkinsonian symptoms does not improve meaningfully on levodopa, MSA moves up the list of possibilities. Physical therapy plays a role in both diseases, though the goals differ. In ALS, the focus is on maintaining mobility and preventing contractures. In MSA, therapy emphasizes balance, fall prevention, and managing the postural instability that comes with cerebellar and basal ganglia damage.

A Quick-Reference Comparison

Seeing the key distinctions side by side can help clarify where the two diseases diverge:

Primary target: ALS attacks upper and lower motor neurons; MSA attacks the autonomic system, cerebellum, and basal ganglia.
Key protein: ALS is associated with TDP-43 aggregates in most cases; MSA is defined by alpha-synuclein deposits in glial cells.
Muscle wasting: Prominent and progressive in ALS; not a typical feature of MSA.
Autonomic failure: Severe and early in MSA (blood pressure drops, bladder problems); mild and late, if present at all, in ALS.
Cognitive impact: Can be substantial in ALS, with up to two-thirds showing some impairment; generally minimal in MSA.
Levodopa response: Not relevant to ALS; poor or absent in MSA (which helps distinguish MSA from Parkinson’s).
Typical survival: ALS averages roughly two to five years from diagnosis; MSA averages roughly six to ten years from symptom onset.

Rare Genetic Overlap

One of the more intriguing findings in recent neurodegenerative research is that certain genetic mutations can produce clinical pictures that look like different diseases in different family members. The C9orf72 gene, which contains a repeat expansion that is the single most common genetic cause of familial ALS, has been identified in families where some members developed ALS and others developed features consistent with MSA or frontotemporal dementia. This does not mean the diseases are the same, but it does suggest that the same genetic vulnerability can tip the nervous system toward different patterns of degeneration depending on other factors that are not yet well understood. For families dealing with one of these diagnoses, the finding underscores the value of genetic counseling, especially when there is a family history of neurodegeneration in any form.

The C9orf72 connection also raises a broader point about how we categorize neurodegenerative diseases. The traditional boundaries between conditions like ALS, MSA, Parkinson’s, and frontotemporal dementia are based on clinical symptoms and pathology findings. But at the molecular level, the boundaries are blurrier than the textbook categories suggest. Proteins misfold, inflammation escalates, mitochondria fail, and cells die through overlapping pathways. Understanding those shared pathways may eventually lead to treatments that help more than one condition, even if the diseases look clinically distinct at the bedside.